Over a 10-year period, METS-IR effectively predicted CV events among patients with PsA, with values greater than 2.48 at baseline conferring the greatest risk.

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Apremilast treatment in patients with psoriatic arthritis leads to favorable changes in body composition and improves disease ...